08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Aptalis Holdings, Forest Laboratories deal

Forest will acquire gastrointestinal company Aptalis for $2.9 billion in cash. Aptalis markets nine products, including Carafate sucralfate suspension to treat active duodenal ulcers and Zenpep pancrelipase to treat exocrine pancreatic insufficiency. For...
08:00 , Jan 13, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) fell $3.58 (15%) to $20.37 on Thursday after disclosing in an SEC filing that FDA has not yet discussed with the company proposed labeling or postmarketing requirements for Feraheme ferumoxytol,...
02:08 , Jan 9, 2014 |  BC Extra  |  Top Story

Forest to acquire Aptalis

Forest Laboratories Inc. (NYSE:FRX) jumped $10.54 (18%) to $69.30 on Wednesday after announcing it will acquire gastrointestinal company Aptalis Holdings Inc. (Bridgewater, N.J.) for $2.9 billion in cash. The move translates to a $2.8 billion...
01:06 , Dec 27, 2013 |  BC Extra  |  Top Story

Aptalis files for $500 million IPO

Gastrointestinal company Aptalis Holdings Inc. (Mont-Saint-Hilaire, Quebec) filed to raise up to $500 million in an IPO underwritten by Goldman Sachs; JPMorgan; Barclays; and Evercore. Aptalis markets nine products, including Carafate sucralfate suspension to treat...
07:00 , Aug 2, 2010 |  BioCentury  |  Regulation

Equivalence test case

While FDA's response to a Citizen's Petition lodged by sanofi-aventis Group specifically addresses the requirements for demonstrating the equivalence of enoxaparin products, it sheds light on the technical rigor that is likely to be necessary...
07:00 , Aug 2, 2010 |  BioCentury  |  Regulation

Equivalence test case

Equivalence test case By Susan Schaeffer Managing Editor While FDA's response to a Citizen's Petition lodged by sanofi-aventis Group specifically addresses the requirements for demonstrating the equivalence of enoxaparin products, it sheds light on the technical rigor...
07:00 , Oct 13, 2003 |  BC Week In Review  |  Company News

Axcan, Aventis deal

AXP acquired North American rights from AVE to duodenal ulcer drug Carafate (Sulcrate in Canada), irritable bowel syndrome (IBS) drug Bentyl (Bentylol in Canada), and hemorrhoidal drug Proctosedyl for $145 million in cash. In 2002,...
07:00 , Oct 13, 2003 |  BioCentury  |  Finance

Ebb & Flow

ID Biomedical'sdecision to raise $100 million in a bought deal less than a week after pulling a proposed follow-on because it thought the price too low could have left some scratching their heads. The deals...
07:00 , Oct 9, 2003 |  BC Extra  |  Company News

Axcan, Aventis GI product deal

Axcan (TSE:AXC; AXCA) acquired North American rights from AVE to duodenal ulcer drug Carafate (Sulcrate in Canada), irritable bowel syndrome drug Bentyl (Bentylol in Canada) and hemorrhoidal drug Proctosedyl for a cash purchase price of...